Q3 FY2026
Filed Nov 5, 2026Sana Biotechnology Q3 2026: GAAP net income of $20.4 million driven by a $63.4 million non-cash gain, while cash fell to $121.7 million with runway guided into mid-2027
The quarter shows GAAP net income only because of a non-cash fair value gain of $63.4 million on success payment and contingent consideration liabilities. Excluding that item, operating expenses rose in the quarter, non-GAAP net loss widened to $43.0 million from $39.0 million, cash and marketable securities declined to $121.7 million, and the company's stated runway extends only into mid-2027. Clinical milestones were reiterated but no financial guidance was given.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Cash, cash equivalents and marketable securities (as of Sep 30, 2026)GAAP | $121.7M | – | – |
| Research and development expenses, three months ended Sep 30, 2026 (inclusive of non-cash expenses)GAAP | $33.9M | – | $3.8 million increase |
| Research and development expenses, nine months ended Sep 30, 2026 (inclusive of non-cash expenses)GAAP | $93.4M | – | $3.7 million decrease |
| Non-cash stock-based compensation in R&D, three months ended Sep 30, 2026GAAP | $3M | – | – |
| Non-cash stock-based compensation in R&D, nine months ended Sep 30, 2026GAAP | $9.3M | – | – |
| R&D related success payments and contingent consideration, three months ended Sep 30, 2026 (non-cash gain)GAAP | gain of $63.4 million | – | – |
| R&D related success payments and contingent consideration, nine months ended Sep 30, 2026 (non-cash gain)GAAP | gain of $31.0 million | – | – |
| General and administrative expenses, three months ended Sep 30, 2026 (inclusive of non-cash expenses)GAAP | $10.9M | – | – |
| General and administrative expenses, nine months ended Sep 30, 2026 (inclusive of non-cash expenses)GAAP | $33.2M | – | – |
| Impairment of long-lived assets, nine months ended Sep 30, 2026GAAP | no impairment recorded | – | – |
| Income (loss) from operations, three months ended Sep 30, 2026GAAP | $18.51M | – | – |
| Income (loss) from operations, nine months ended Sep 30, 2026GAAP | −$95.53M | – | – |
| Interest income, net, three months ended Sep 30, 2026GAAP | $1.22M | – | – |
| Interest income, net, nine months ended Sep 30, 2026GAAP | $3.30M | – | – |
| Other income, net, three months ended Sep 30, 2026GAAP | $676K | – | – |
| Other income, net, nine months ended Sep 30, 2026GAAP | $1.78M | – | – |
| Net income (loss), three months ended Sep 30, 2026GAAP | $20.4M | – | – |
| Net income (loss) per share, three months ended Sep 30, 2026 (basic and diluted)GAAP | $0.07 | – | – |
| Net income (loss), nine months ended Sep 30, 2026GAAP | −$90.4M | – | – |
| Net income (loss) per share, nine months ended Sep 30, 2026 (basic and diluted)GAAP | $(0.31) | – | – |
| Net loss, three months ended Sep 30, 2026non-GAAP | −$43M | – | – |
| Net loss per share, three months ended Sep 30, 2026non-GAAP | $(0.14) | – | – |
| Net loss, nine months ended Sep 30, 2026non-GAAP | −$121.5M | – | – |
| Net loss per share, nine months ended Sep 30, 2026non-GAAP | $(0.41) | – | – |
| Operating cash burn, nine months ended Sep 30, 2026non-GAAP | $103.4M | – | – |
| Cash used in operations, nine months ended Sep 30, 2026GAAP | $108.9M | – | – |
| Net proceeds from equity financings, nine months ended Sep 30, 2026GAAP | $93.3M | – | – |
Capital returns
- No share repurchases or dividends are reported in the filing.
- Net proceeds from equity financings were $93.3 million for the nine months ended Sep 30, 2026, per the filing text.
What drove it
- The company attributes the $3.8 million increase in three-month R&D to higher third-party manufacturing costs at CDMOs for the SC451 and SG293 programs and higher laboratory costs related to SC451, partially offset by prior-year CDMO and clinical trial costs for the suspended allogeneic CAR T programs that did not recur.
- The company attributes the $3.7 million decrease in nine-month R&D mainly to lower personnel-related expenses, including non-cash stock-based compensation, lower facility and other allocated costs, and non-recurrence of prior-year CDMO costs for the suspended allogeneic CAR T programs. Higher SC451 laboratory costs and higher CDMO costs for SC451 and SG293 partially offset these reductions.
- The company attributes the three-month gain of $63.4 million on success payment and contingent consideration liabilities primarily to the August 2026 amendment to the Cobalt acquisition agreement, which accounts for $55.5 million of that gain.
- The company attributes the increases in three-month and nine-month G&A to higher facility and other allocated costs.
- Per the filing, the 2025 impairment of $44.6 million was primarily related to the Bothell, Washington manufacturing facility and certain laboratory and office space in Seattle, Washington, after the company suspended further internal manufacturing build-out in the second quarter of 2025.
Concerns
- Q3 GAAP net income of $20.4 million depends on a non-cash gain of $63.4 million from fair value changes in success payment and contingent consideration liabilities. The filing states that these liabilities may fluctuate significantly with development timing, probability, business development payments and market capitalization.
- Non-GAAP net loss for the three months widened to $(43.0) million from $(39.0) million a year earlier, and non-GAAP net loss per share was $(0.14) against $(0.15).
- Cash and marketable securities fell to $121.7 million, and the company states its runway extends into mid-2027.
- Three-month R&D rose to $33.9 million from $30.1 million, attributed by the company to CDMO and laboratory costs for SC451 and SG293.
- The filing says the company's clinical timelines are subject to change and that IND acceptance is at FDA's discretion, as stated in the forward-looking statements section.
What to watch
- Filing of the IND and start of the SC451 Phase 1/2 trial in type 1 diabetes, which the company says may begin as early as this year.
- Start of the SG293 clinical study in non-Hodgkin lymphoma, which the CEO's quote places in 1Q 2027, and the potential first-in-human data as early as the first half of 2027.
- Clinical study start for SG227 in multiple myeloma, which the company says may occur as early as 2027, contingent on the early clinical profile of SG293.
- Timing of the company's stated cash runway into mid-2027 and any further equity financing.
- Future changes in the fair value of success payment and contingent consideration liabilities, including the Cobalt amendment effects and any business development transactions involving the fusogen technology.
- Progress of the Mayo Clinic collaboration for SC451 development and standardization.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $121.7 million at Sep 30, 2026, compared with $138.4 million at Dec 31, 2025, a decrease of $16.7 million.
- The company attributes the decrease primarily to cash used in operations of $108.9 million and cash used for purchases of property and equipment of $2.7 million, partially offset by net proceeds from equity financings of $93.3 million.
- Total assets were $376,127 thousand at Sep 30, 2026, compared with $416,890 thousand at Dec 31, 2025.
- Total liabilities were $195,763 thousand at Sep 30, 2026, compared with $256,006 thousand at Dec 31, 2025.
- Total stockholders' equity was $180,364 thousand at Sep 30, 2026, compared with $160,884 thousand at Dec 31, 2025.
- Contingent consideration liability was $95,357 thousand at Sep 30, 2026, compared with $123,718 thousand at Dec 31, 2025. Success payment liabilities were $16,566 thousand, compared with $19,238 thousand.
- The company states that its expected cash runway extends into mid-2027.
Analysis
Sana reported a third quarter in which GAAP net income of $20.4 million, or $0.07 per share, was produced by a $63.4 million non-cash gain tied to success payment and contingent consideration liabilities. The company attributes $55.5 million of that gain to changes in the estimated fair value of the Cobalt contingent consideration, primarily reflecting the August 2026 amendment to the Cobalt acquisition agreement. Excluding this item, the operating picture is a cost base in which three-month R&D rose to $33.9 million from $30.1 million and G&A rose to $10.9 million from $10.3 million. The company gives the R&D increase as higher CDMO and laboratory costs for SC451 and SG293. The nine-month figures show a different pattern, with R&D down to $93.4 million from $97.1 million, which the company ties to lower personnel costs and the non-recurrence of prior-year costs for suspended allogeneic CAR T programs.
On a non-GAAP basis, the quarter was a loss. Non-GAAP net loss was $(43.0) million, or $(0.14) per share, against $(39.0) million, or $(0.15) per share, a year earlier. For the nine months, non-GAAP net loss was $(121.5) million, or $(0.41) per share, compared with $(125.4) million, or $(0.51) per share. Non-GAAP operating cash burn for the nine months was $103.4 million, against $108.0 million in the prior year period. These measures exclude the fair value changes and the 2025 impairment, which the company describes as non-cash.
On the balance sheet, cash, cash equivalents and marketable securities declined from $138.4 million at December 31, 2025 to $121.7 million at September 30, 2026. The company attributes the decline mainly to $108.9 million of cash used in operations and $2.7 million of capital expenditures, partly offset by $93.3 million of net equity proceeds. Total liabilities fell to $195,763 thousand from $256,006 thousand, mainly reflecting the lower contingent consideration and success payment balances, and stockholders' equity rose to $180,364 thousand from $160,884 thousand. The company states that its expected cash runway extends into mid-2027, which is the reference point for any future financing needs.
The filing gives no financial guidance for revenue, margins, expenses or tax, so there is no guidance comparison. The forward-looking content is clinical and timing-based. The company expects to file an IND and begin a Phase 1/2 trial for SC451 as early as this year, to start SG293 clinical work in 1Q 2027 according to the CEO quote, and to share SG293 first-in-human data as early as the first half of 2027. SG227 clinical testing is described as possible as early as 2027, contingent on the early clinical profile of SG293. The 14-month UP421 investigator-sponsored study results and the NEJM letter are presented as supporting context for the SC451 program.
The key figures for a reader are the composition of Q3 net income, the widening of the non-GAAP loss in the quarter, and the cash balance relative to the mid-2027 runway. The filing does not disclose share price reaction, analyst expectations or consensus, and none are included here.
Management, verbatim
We aim to share data from both of these programs in 2027 and anticipate both have the potential for relatively rapid proof of concept.
Steve Harr, President and Chief Executive Officer
Not in the filing
stated, not guessed- Revenue, gross margin and cost of sales: the filing reports no revenue or cost of sales lines.
- Financial guidance for operating expenses, tax rate or any other financial metric: not provided in the filing.
- Prior-year and prior-quarter cash balances for the same period: the comparison given is to December 31, 2025, not to the prior year period or prior quarter.
- Quarter-over-quarter (prior quarter) figures for any line: not printed in the filing.
- Dollar amount of the year-over-year change in three-month and nine-month G&A: the filing states the increase but does not print its amount.
- Non-GAAP research and development and non-GAAP general and administrative expense figures: the filing names these measures but does not print their values.
- Share price reaction, consensus estimates and analyst expectations: not in the filing.
- Prior-year figure for net proceeds from equity financings in a comparable presentation: not stated in the text in a directly comparable form.
- Three-month non-cash stock-based compensation change in G&A for year-over-year comparison beyond the printed prior-year figure: amounts printed, change not stated.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.